Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR

References

• Kadia TM, Ravandi F, O’Brien S, et al. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; pii: S2152-2650(14)00409-1
   Google Scholar
• Cabanillas F. Non-Hodgkin’s lymphoma: the old and the new. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S87-90
   PubMedGoogle Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013;31(32):4123-31
   PubMed Web of Science ®Google Scholar
• Galimberti S, Luminari S, Ciabatti E, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res 2014;20(24):6398-405
   PubMed Web of Science ®Google Scholar
• Sutton R, Shaw PJ, Venn NC, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol 2014;168(3):395-404
   PubMed Web of Science ®Google Scholar
• Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 2014;5(15):6280-8
   PubMedGoogle Scholar
• Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31(20):2540-7
   PubMed Web of Science ®Google Scholar
• Toft N, Birgens H, Abrahamsson J, et al. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 2013;90(5):404-12
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28(10):1988-92
   PubMed Web of Science ®Google Scholar
• Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010;22(6):656-63
   PubMed Web of Science ®Google Scholar
• Simonsen AT, Sørensen CD, Ebbesen LH, et al.11 as a minimal residual disease marker for Mantle cell lymphoma. Leuk Res 2014;38(8):918-24
   PubMed Web of Science ®Google Scholar
• Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech 2014;7(8):941-51
   PubMed Web of Science ®Google Scholar
• Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006;20(7):1217-20
   PubMed Web of Science ®Google Scholar
• Kristensen T, Møller MB, Friis L, et al.1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011;87(5):400-8
   PubMed Web of Science ®Google Scholar
• Szczepański T, Willemse MJ, Brinkhof B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002;99(7):2315-23
   PubMed Web of Science ®Google Scholar
• Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007;92(7):970-3
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, Van der Velden VHJ, et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17(12):2318-57
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, Van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17(12):2474-86
   PubMed Web of Science ®Google Scholar
• Van der Velden VHJ, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21(4):604-11
   PubMed Web of Science ®Google Scholar
• Müller MC, Hördt T, Paschka P, et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004;112(1-2):30-3
   PubMed Web of Science ®Google Scholar
• Moppett J, Van der Velden VHJ, Wijkhuijs AJM, et al. Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin. Leukemia 2003;17(1):268-70
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55(4):611-22
   PubMed Web of Science ®Google Scholar
• Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant 2008;42(3):187-96
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88(6):2267-78
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27(31):5195-201
   PubMed Web of Science ®Google Scholar
• White H, Deprez L, Corbisier P, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008;22(1):96-102
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17(12):2257-317
   PubMed Web of Science ®Google Scholar
• Østergaard M, Nyvold CG, Jovanovic JV, et al. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 2011;25(7):1168-73
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27(26):4365-70
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Venturi C, et al. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 2014;38(5):581-5
   PubMed Web of Science ®Google Scholar
• Ladetto M, Brüggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014;28(6):1299-307
   PubMed Web of Science ®Google Scholar
• Thol F, Kölking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012;51(7):689-95
   PubMed Web of Science ®Google Scholar